Lakewood-Amedex Biotherapeutics Inc. fell 17.2% on Thursday, October 29, 2026, on 4,128,300 shares. No headline about LABT came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Lakewood-Amedex Biotherapeutics Inc. (LABT:NASDAQ) closed at $0.185 on November 2, 2026, down 7.50% on the day. The stock trades 99.8% below its 52-week high of $98.20 and 9.7% above its 52-week low of $0.169. Over the past year, it lost 99.8%. Lakewood-Amedex Biotherapeutics Inc. is part of the Health Care sector.
In 133 trading sessions since April 24, 2026, LABT closed higher on 44 days (33%). Its best day was July 22, 2026 (+83.33%) and its worst was April 27, 2026 (-50.20%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 3 times.
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. Antimicrobial resistance (AMR) represents a growing global health crisis, contributing to nearly 5 million deaths worldwide. The company's lead product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). Diabetic foot ulcer impacts approximately 13 million people in the U.S. with 50 percent experiencing infections at least once in their lifetime.
Find more stocks like LABT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.